| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 5 | | | |
| | | | 7 | | | |
| | | | 10 | | | |
| | | | 14 | | | |
| | | | 19 | | | |
| | | | 23 | | | |
| | | | 24 | | | |
| | | | 26 | | | |
| | | | 29 | | | |
| | | | 35 | | | |
| | | | 35 | | | |
| | | | 36 | | |
Proposal
|
| |
Vote Required
|
| |
Broker
Discretionary Voting Allowed |
| |
Effect of Abstentions and Broker Non-Votes
|
|
Proposal 1 — To elect two directors of the Company nominated by the Board and named in this proxy statement who will each serve for a term of three years and until their successors are duly elected and qualify | | | Affirmative vote of a plurality of all the votes cast at the Annual Meeting | | |
No
|
| | Broker non-votes are not counted as votes cast for purposes of the election of directors and, therefore, will have no effect on the outcome of such election. A proxy marked “withhold” with respect to a director nominee will result in such director nominee receiving one fewer “FOR” vote that would count towards a plurality. | |
Proposal 2 — To ratify the selection of RSM US LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022 | | | Affirmative vote of a majority of the votes cast at the Annual Meeting | | |
Yes
|
| | Abstentions will not be included in determining the number of votes cast and, as a result, will not have any effect on the result of the vote on this proposal. | |
Proposal 3 — To approve a proposal to authorize the Company to issue options, warrants or securities to | | | Affirmative vote of a majority of the votes cast at the Annual Meeting in person | | |
No
|
| | Abstentions and broker non-votes will have no effect on the result of the vote. | |
Proposal
|
| |
Vote Required
|
| |
Broker
Discretionary Voting Allowed |
| |
Effect of Abstentions and Broker Non-Votes
|
|
subscribe to, convert to, or purchase common stock, subject to the conditions as set forth in the proxy statement | | | (virtually) or by proxy. | | | | | | | |
Proposal 4 — To approve of the Company becoming subject to a minimum asset coverage ratio of at least 150%, permitting the Company to double its amount of debt incurrence, pursuant to Section 61(a)(2) of the Investment Company Act of 1940, as amended by the Small Business Credit Availability Act | | | Affirmative vote of a majority of the votes cast at the Annual Meeting in person (virtually) or by proxy. | | |
No
|
| | Abstentions and broker non-votes will have no effect on the result of the vote. | |
Name and Address of Beneficial Owner
|
| |
Number of Shares
Owned Beneficially(1) |
| |
Percentage
of Class |
| ||||||
Interested Directors: | | | | | | | | | | | | | |
R. David Spreng
|
| | | | 171,584(4) | | | | | | * | | |
Brian Laibow
|
| | | | — | | | | | | * | | |
Independent Directors: | | | | | | | | | | | | | |
Gary Kovacs
|
| | | | 48,179 | | | | | | * | | |
Julie Persily
|
| | | | 14,454 | | | | | | * | | |
Lewis W. Solimene, Jr.
|
| | | | 14,454 | | | | | | * | | |
Executive Officers Who Are Not Directors: | | | | | | | | | | | | | |
Thomas B. Raterman
|
| | | | 96,457(5) | | | | | | * | | |
Joseph McDermott
|
| | | | — | | | | | | * | | |
Executive officers and directors as a group
|
| | | | 259,796 | | | | | | * | | |
5% or More Holders: | | | | | | | | | | | | | |
OCM Growth Holdings, LLC(2)
|
| | | | 20,765,158 | | | | | | 50.2% | | |
Carilion Clinic(3)
|
| | | | 2,408,965 | | | | | | 5.8% | | |
Retirement Plan of Carilion Clinic(3)
|
| | | | 2,408,965 | | | | | | 5.8% | | |
Name
|
| |
Dollar Range of Equity
Securities Beneficially Owned(1)(2)(3) |
|
Interested Directors: | | | | |
R. David Spreng
|
| | Over $100,000 | |
Brian Laibow
|
| | None | |
Name
|
| |
Dollar Range of Equity
Securities Beneficially Owned(1)(2)(3) |
|
Independent Directors:
|
| | | |
Gary Kovacs
|
| | Over $100,000 | |
Julie Persily
|
| | Over $100,000 | |
Lewis W. Solimene, Jr.
|
| | Over $100,000 | |
Name
|
| |
Age
|
| |
Position
|
| |
Expiration of Term
|
| |
Director
Since |
| |||
R. David Spreng | | | | | 60 | | | |
Chairman of the Board (Interested),
Chief Executive Officer and President |
| |
2022
|
| |
2015
|
|
Brian Laibow | | | | | 44 | | | | Director (Interested) | | |
2022
|
| |
2017
|
|
Name
|
| |
Age
|
| |
Position
|
| |
Expiration of Term
|
| |
Director
Since |
| |||
Gary Kovacs | | | | | 58 | | | |
Director (Independent)
|
| |
2023
|
| |
2016
|
|
Name
|
| |
Age
|
| |
Position
|
| |
Expiration of Term
|
| |
Director Since
|
| |||
Julie Persily | | | | | 56 | | | |
Director (Independent)
|
| |
2024
|
| |
2017
|
|
Lewis W. Solimene, Jr. | | | | | 62 | | | |
Director (Independent)
|
| |
2024
|
| |
2017
|
|
Name
|
| |
Age
|
| |
Position
|
| |
Officer Since
|
| |||
Thomas B. Raterman | | | | | 62 | | | |
Chief Operating Officer, Chief Financial Officer,
Treasurer and Secretary |
| |
2015
|
|
Joseph McDermott | | | | | 53 | | | | Chief Compliance Officer | | |
2021
|
|
Name
|
| |
Fees Earned
or Paid in Cash(1) |
| |
All Other
Compensation(2) |
| |
Total
|
| |||||||||
Interested Directors | | | | | | | | | | | | | | | | | | | |
R. David Spreng
|
| | | | — | | | | | | — | | | | | | — | | |
Brian Laibow
|
| | | | — | | | | | | — | | | | | | — | | |
Independent Directors | | | | | | | | | | | | | | | | | | | |
Gary Kovacs
|
| | | $ | 97,500 | | | | | | — | | | | | $ | 97,500 | | |
Julie Persily
|
| | | $ | 93,750 | | | | | | — | | | | | $ | 93,750 | | |
Lewis W. Solimene, Jr.
|
| | | $ | 97,500 | | | | | | — | | | | | $ | 97,500 | | |
| | |
Fiscal Year Ended
December 31, 2021 |
| |
Fiscal Year Ended
December 31, 2020 |
| ||||||
Audit Fees
|
| | | $ | 750,019 | | | | | $ | 472,494 | | |
Audit-Related Fees
|
| | | | — | | | | | | — | | |
Tax Fees
|
| | | | 21,250 | | | | | | 20,250 | | |
All Other Fees
|
| | | | — | | | | | | — | | |
Total Fees:
|
| | | $ | 771,269 | | | | | $ | 492,744 | | |
|
Assumed Return on Our Portfolio (net of expenses)(1)
|
| | | | (10.0)% | | | | | | (5.0)% | | | | | | 0.0% | | | | | | 5.0% | | | | | | 10.0% | | |
|
Corresponding Net Return to Common Stockholders
|
| | | | (12.6)% | | | | | | (6.6)% | | | | | | (0.5)% | | | | | | 5.6% | | | | | | 11.7% | | |
|
Assumed Return on Our Portfolio (net of expenses)(1)
|
| | | | (10.0)% | | | | | | (5.0)% | | | | | | 0.0% | | | | | | 5.0% | | | | | | 10.0% | | |
|
Corresponding Net Return to Common Stockholders
|
| | | | (37.0)% | | | | | | (22.0)% | | | | | | (7.0)% | | | | | | 8.0% | | | | | | 23.0% | | |
| | |
Actual as of
December 31, 2021 |
| |
Assumed 150% Asset
Coverage Ratio |
| ||||||
Management Fee payable under the Investment Advisory Agreement(1)
|
| | | | 1.48% | | | | | | 4.50% | | |
Incentive Fee payable under the Investment Advisory Agreement(2)
|
| | | | 1.52% | | | | | | 5.76% | | |
Interest payments on borrowed funds
|
| | | | 0.42%(3) | | | | | | 7.02%(4) | | |
Other expenses(5)
|
| | | | 1.00% | | | | | | 1.00% | | |
Total annual expenses
|
| | | | 4.42% | | | | | | 18.28% | | |
| | |
1 Year
|
| |
3 Years
|
| |
5 Years
|
| |
10 Years
|
| ||||||||||||
Total Expenses Incurred(1)
|
| | | $ | 46 | | | | | $ | 140 | | | | | $ | 234 | | | | | $ | 472 | | |
Total Expenses Incurred(2)
|
| | | $ | 192 | | | | | $ | 498 | | | | | $ | 723 | | | | | $ | 1,060 | | |